Welcome to
Greenwich LifeSciences
Greenwich LifeSciences (Nasdaq: GLSI) is a public clinical-stage biopharmaceutical company focused on the development of an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery.
Greenwich LifeSciences’ lead product is GP2, an immunotherapy derived from the HER2/neu protein that is expressed in breast cancer and many other common cancers.
Multiple Studies Have Shown Both Safety and Efficacy
Greenwich LifeSciences has commenced Flamingo-01, a Phase III clinical trial, with plans to expand from the US into Europe and to open up to 150 sites globally. Flamingo-01 is designed to evaluate the safety and efficacy of GLSI-100 in HER2/neu positive patients with residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment.
Follow The News
Greenwich LifeSciences completed its Initial Public Offering on the Nasdaq Capital Market on September 25, 2020, under the symbol “GLSI.”
